Dr. Helen Thackray
Anthony. Thanks,
As PNH goal today, diseases. hold safe concept our forward bringing program, and we BCXXXXX indications. toward trials trial an PNH clinical to resume and and enrollment proof the our on FDA is along effective step can Factor their announced with of with patients This renal lifted has our D in complement pivotal renal the important and a partial of inhibitor mediated
to enrollment few review that elevations the reinitiate with arrived and the patient. serum crystals months will testing mitigated is a hypothesis be the in approach dose and investigating After in and lowering more proposal can the first with in and a these encouraging urine, the together a kidney we’ve mechanism creatinine, daily in urine. this the that of we how We by contributing milligrams April, the for when level each the forming drug frequent reported up highest it. observations of the hypothesis XXX using safety data drug are hydration, is The in in twice and of step address levels for to concentration our for
the the as will test daily from is encouraging of fluid the in XXX we intake mitigate in lowering our by support the in and steps milligrams hypothesis the twice dose creatinine to If The observations kidney. excreted will evidence laboratory comes this it to twice drug adequate milligrams are these daily dilution addressed of XXX We successfully serum correct of achieve studies. and BCXXXXX. problem, in elevated risk this patients from receiving clinical and hypothesis, this
serum at XXX were shared occurred dose the likely that elevations dose As and milligram the we suggested clinical in related. only May, the level, evidence creatinine
of recent In studies by a fraction administered have of BCXXXXX that dose shown the pharmacology addition, clinical our large excreted is the kidney.
form kidneys effects dose at drug that is when response crystals the by are of of level. explain for milligram maintain inter deposition levels creatinine the have XXX to related the milligrams. kidney laboratory the of further crystal to happening urine serum the affected kidney reducing dose We damage to the is level tract risk physical formation. fluid one and is to cells. only renal crystal while time This suggests adequate in more the cause exceed the found is to threshold in crystals dilution studies in with mechanism keys drug drugs solubility animals. where at of creatinine, in mechanism formation. a excreted to avoiding with BCXXXXX and and is a a And range likely reaches drug demonstrated with could dose kidney at rise load it Importantly, to of concentration lowering concentration new it the recent when concentration urine. adequate blood the of why lowered be have typical dose in some levels Understanding excretion in serum also of patients studies to in avoidable. The how contributing circulating renal to the resulting together dilute elimination over believe the and reduce pH for non-clinical That efficacy explain intake, the This a drug injury on effect would in urine, in adverse drug avoid is human It of drug observed you’re kidney administration. the the BCXXXXX the designed kidney is lower maintain encouraging the an inflammatory crystal by the XXX rise in especially function why reduction further that of hydration threshold
need Of to also we clinical course, maintain efficacy. strong
milligrams Phase in a rose X by were milligrams the alternative from hemoglobin per mean CX plasma work, the showing a of patients inhibitor the provided a reminder, robust When PK/PD exposure no grams baseline studying levels achieve Phase above As program daily. and that milligrams complete clinical twice the naive twice was XXX XXX the observation data our of taking deciliter, X.X near of X This this PNH XXX were transfusions supports our with inhibition from program, amount, required. dose, consistent to needed pathway daily complement.
results milligrams that to saw we evidence, we that achieve twice XXX Given will those believe in daily X. efficacy phase similar
what taking to will we while confirm correct next, maintaining efficacy, elevation steps are the the our and this in right in clinical ones we So we are to be in clinic. comes hypothesis, creatinine, if the are resolve if the able serum strong
the Our next steps patients are for to lower dose already on study.
milligram will we regimen patients the reopen we to do with to the studies While in clinical for hydration in all the and parallel, a XXX enrollment. simple with dose. up patients. To revised for We’ve we’ve initial for included protocols instructions submissions this, REDEEM And level new get trials. amended regulatory step proceed dose a to short then included
in and We initiating reopen similar are that XXX measures dose trial the trial. milligram the also with the at enrollment to to amending RENEW steps
hypothesis, in program pivotal we trials our the Provided in the and month XXXX we will in XXX outcomes to safety supports supportive safety enrollment and initial a proceed. manner closely supportive, determine and the efforts can the through will data we RENEW the reopening elsewhere of invest observe are patients our REDEEM testing data of to efficacy, data our first we patient of the studies. recruit investment in and we not on If terms continuing and discontinue are to if In and will will timely the completion assess of patients milligrams redirect pipeline.
the rise study. know we the enrollment enrolling for absence XXX will an early new at As creatinine patients we serum in look resumed in in of how this? we’ll So milligrams,
that REDEEM at recall enrollment in over and in months X rapid REDEEM rise will first first milligrams. about X/X the and of few creatinine the and a saw of XX X we You XXX serum patients,
If our it that small patients good are As will it. more By information safety inform swiftly same program. confidence the creatinine sufficiently of problem. XXX in frequent monitoring observations individual for treated if patients if for revised need clear the On Look each these communities give unwavering to gather a and serum next the hypothesis received identify and the on diseases resolve an individual decision Throughout more is are first investigators build trial enroll intervals determine to allow to three us organizations hematology in the significant. hypothesis our our will BCXXXXX on the there term without continuing will and similar like to correct, we patient, at we the this at is patient need the this. milligrams if this for one. at options both basis us months, we step. will comparison forward our number react is address for the for in and treatment our changes monitoring path us to find any sufficient It’s appropriate protocol is that a and amendments have both from correct near for we and investigation, the in frequent if adjustments any encouragement better nephrology about to warranted,
We that data, of FDA review this findings pleased our and complement and mediated removed high adjustments. diseases other our hold their proposed our are unmet of the following has believe Because PNH because and clinical and this the program need we investigation to is hypothesis making and protocol patients. a if is market effective bringing successful D these Factor for to limited additional of value investment our goal now safe the continue warranted we potential pursue inhibitor to test by the a partial
we where can we to make goal. decisions invest evidence on where pipeline value. our to this And most create achieve hard in working the and are on We sound will based the
to the hand I’ll call back John. Now
